MP78-03 TESTOSTERONE LEVELS FOLLOWING RADIATION THERAPY FOR PROSTATE CANCER

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Evaluation II (MP78)1 Apr 2020MP78-03 TESTOSTERONE LEVELS FOLLOWING RADIATION THERAPY FOR PROSTATE CANCER Justin Haseltine*, Nicole Benfante, Michael Zelefsky, and John Mulhall Justin Haseltine*Justin Haseltine* More articles by this author , Nicole BenfanteNicole Benfante More articles by this author , Michael ZelefskyMichael Zelefsky More articles by this author , and John MulhallJohn Mulhall More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000964.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The impact of radiotherapy (RT) with androgen deprivation therapy (ADT) on testosterone (T) levels has been well documented. However, the data on the impact of RT monotherapy on T levels is less clear. We report our experience examining T profiles after RT without ADT for prostate cancer (PC). METHODS: The study population included patients who received RT for PC without ADT who had pre -RT (within 6 months of RT commencement) and post-RT total T (TT) levels collected before noon, measured using LCMS at a single lab. Patients with baseline castrate TT levels (TT<50) were excluded. Demographic, comorbidity, pathological and RT dosing data were recorded. Predictors of TT decreases were analyzed using logistic regression. Factors entered in to the model included: patient age, TT levels pre-RT, type of RT, and presence of hypertension (HTN), diabetes (DM), or cigarette smoking history. RESULTS: 168 patients have complete information and were included in the analysis. Median age was 68 (IQR 61, 71) and median pre-RT TT was 362 (IQR 299, 451). The majority of biopsy Gleason scores were 6 (30%) or 7 (61%). Comorbidities included HTN (46%), DM (13%), and smoking history (42%). RT was delivered as brachytherapy (BT) (11%), external beam RT (EBRT) alone (64%) or EBRT + BT (24%). Median time-point at the last TT measurement was 36 months (IQR 16, 70). Median number of TT levels was 3 (IQR 2, 5). Median TT at 6 and 24 months was 356 and 404, respectively. Pre-RT, TT was <300 ng/dL in 26% of patients. There was a decrease in TT from baseline of >100, >200, or >300 ng/dL post-RT in 43%, 17%, and 6%, respectively. No predictors of TT decreases were identified. CONCLUSIONS: Almost one quarter of men had a significant (≥200 point) decrease in total T levels within 3 years of RT completion. These data suggest that men after RT monotherapy should have their T levels monitored. Source of Funding: NIH grant P30 CA 008748 © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1174-e1174 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Justin Haseltine* More articles by this author Nicole Benfante More articles by this author Michael Zelefsky More articles by this author John Mulhall More articles by this author Expand All Advertisement PDF downloadLoading ...